Ranbaxy Hit By EU Pay-For-Delay Fine Of $13.7 Million
This article was originally published in PharmAsia News
Executive Summary
Troubled Ranbaxy Laboratories has been hit by another charge, this one a $13.7 million fine imposed by the EU for antitrust violations involving pay-for-delay activity.